Matrix metalloproteinases (MMPs) 
Introduction
The matrix metalloproteinases (MMPs) belong to a large subgroup of proteinases which includes the collagenases, gelatinases and the stromelysins, all of which contain tightly bound zinc (Birkedal-Hansen, 1995; Ries and Petrides, 1995) . Several MMPs have been identified but the exact role of their involvement in various physiological and pathological processes is only incompletely understood. There is emerging evidence that MMPs might be involved in the pathogenesis of inflammatory demyelinating disorders such as multiple sclerosis and the Guillain-Barré syndrome (Opdenakker and van Damme, 1994) . In a first study, Cuzner et al. (1978) demonstrated increased neutral proteinase activity in the CSF during exacerbations of multiple sclerosis. More recently,
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certain MMPs, i.e. 72-kDa gelatinase, stromelysin-1, interstitial collagenase, matrilysin (MMP-7) and 92-kDa gelatinase (MMP-9), were shown to degrade myelin basic protein (MBP) in vitro (Chandler et al., 1995) . Furthermore, evidence is emerging that MMPs might be involved in bloodbrain barrier (BBB) breakdown. Thus, non-specific inhibition of MMPs was shown to protect the BBB and could suppress, and even reverse, ongoing experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (Gijbels et al., 1994; Hewson et al., 1995) . Among all known MMPs, the 92-kDa gelatinase might be particularly involved in BBB breakdown, as increased CSF levels of 92-kDa gelatinase in multiple sclerosis patients are associated with a leaky BBB on magnetic resonance imaging (Rosenberg et al., 1996) . Moreover, in multiple sclerosis lesions increased levels of 92-kDa gelatinase were described (Cuzner et al., 1996) , where endothelial cells, astrocytes and microglia were all thought to be potential source of production (Maeda and Sobel, 1996) . However, besides a recent report on MMP expression and its regulation by a hydroxamate-based inhibitor in actively induced EAE (Clements et al., 1997) , there are no data about the temporospatial regulation of 92-kDa gelatinase and other MMPs during the course of neuroinflammatory diseases.
Material and methods Animals
Eight-week-old female Lewis rats (Charles Rivers, Sulzfeld, Germany) weighing 130-145 g were used. Animals were kept in plastic cages and given food and water ad libitum. All experiments were conducted according to Bavarian state regulations for animal experimentation and approved by the responsible authorities.
Induction of EAE
Adoptive transfer (AT)-EAE was induced by tail vein injection of 8ϫ10 6 activated autoreactive T cells specific for MBP. The encephalitogenic CD4 ϩ T-cell line (line MBP.15) was isolated and activated prior to injection as described elsewhere (Jung et al., 1995) . Normal rats and rats injected with ovalbumin specific T cells (line OVA.2, fourth restimulation cycle) served as controls. After 2, 3, 4, 5, 7 and 11 days, groups of three animals each were sacrified and the spinal cord was flash frozen in liquid nitrogen and stored at -70°C.
Clinical scoring of EAE
Animals were weighed and clinically scored daily on a fivepoint scale as follows: grade 0 ϭ no neurological signs; grade 1 ϭ limp tail; grade 2 ϭ mild paraparesis of the hind limbs, unsteady gait; grade 3 ϭ moderate paraparesis, voluntary movements still possible; grade 4 ϭ paraplegia or tetraplegia; grade 5 ϭ moribund.
Competitive polymerase chain reaction (PCR)
For quantification of rat MMP mRNA levels, PCR using a multi-competitor DNA standard was performed (Wells et al., 1996) . The synthetic standard DNA contained tandem arrays of 5Ј and 3Ј priming sites for complementary DNAs (cDNAs) of different MMPs and β-actin.
Primer pairs for collagenase-3, MMP-7, 72-kDa and 92-kDa gelatinase, stromelysin-1 and -3, and β-actin were used according to the sequences published elsewhere (Wells et al., 1996) . Poly(A) ϩ RNA was extracted from frozen spinal cord and used as a template for cDNA synthesis using AMV reverse transcriptase (Promega, Madison, Wis., USA). Threefold serial dilutions of competitive standard DNA were combined with a definite amount of sample cDNA, and PCR was performed in 50-µl reactions containing 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl at pH 9.0 and 0.1% Triton X-100 in the presence of 200 µM dNTP (Pharmacia, Freiburg, Germany), 50 pmol sense and antisense MMP primers, 1 U taq DNA polymerase (Perkin Elmer, Branchburg, NJ), and 1 µCi [ 32 P]α-dCTP (Amersham, Braunschweig, Germany).
Amplification was carried out using 35 cycles (95°C for 30 s, 57°C for 30 s, 72°C for 120 s) in a Hybaid Omnigene thermal cycler (MWG Biotech, Ebersberg, Germany). Ten microlitres of the reaction products were electrophoresed on a 6% polyacrylamide gel. Gels were stained with ethidium bromide and the bands were cut out, added to 2 ml of scintillation fluid and counts per minute were measured in a liquid scintillation counter (Packard Instrument, Downers Grove, Ill., USA). MMP mRNA levels were determined by plotting the ratio of sample cDNA to standard DNA against the standard dilution using a double-logarithmic scale.
Gelatin zymography
Gelatinase activity was determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography modified according to the method of Brown et al. (1990) . Ten 10-µm frozen sections of spinal cord were incubated with 25 µl of Tris/glycine SDS sample buffer (Novex, San Diego, Calif., USA), degraded by ultrasound and further homogenized by vortexing for 1 h at 4°C. The samples were applied to a 10% (w/v) polyacrylamide resolving gel containing 0.1% SDS and 0.1% gelatin type A from porcine skin (Sigma, St Louis, Mo., USA). Stacking gels were 3% (w/v) polyacrylamide. After electrophoresis gels were washed in renaturing buffer (Novex) containing Triton X-100 to remove any SDS, and incubated in developing buffer (Novex) for 18 h at 37°C. Gels were stained for 6 h in 30% methanol : 10% acetic acid containing 0.5% (w/v) Coomassie Brilliant Blue G-250 and destained in the same buffer without dye. Gelatinase activity was detected as unstained bands on a blue background representing areas of gelatin digestion.
Supernatants from tumour necrosis factor (TNF)-α stimulated astrocyte cell cultures, which are known to express 92-kDa and 72-kDa gelatinase in response to cytokine stimulation in vitro (Gottschall and Yu, 1995) , served as positive controls.
Immunohistochemistry
Frozen sections (10 µm) of spinal cord were air dried and fixed for 10 min in 4% formalin and 2 min each of 50%, 100%, then 50% acetone at room temperature. A monoclonal affinity-purified antibody against 92-kDa gelatinase was used at 1.2 µg/ml overnight at 4°C. Thereafter, a biotinylated secondary antibody against mouse IgG and an avidinbiotinylated peroxidase complex (Dako, Hamburg, Germany) were used with 3,3Ј-diaminobenzidine as peroxidase substrate. Endogenous peroxidase activity was suppressed by incubating the sections with 3% H 2 O 2 in methanol for 10 min prior to the secondary antibody. Sections were counterstained with haematoxylin, dehydrated, and mounted in Eukitt (Kindler, Freiburg, Germany).
Double immunofluorescence labelling was performed in an attempt to co-localize MMP-9 expression with inflammatory cells. Frozen sections prepared as above were incubated with the anti-92-kDa gelatinase antibody, which was detected using a monoclonal TRITC (trimethylrhodamine isothiocyanate)-conjugated secondary antibody against mouse IgG (Dianova, Hamburg, Germany). Afterwards the sections were doublestained by sequential incubation with either an FITC (fluorescein isothiocyanate)-conjugated monoclonal antibody specific for rat monocytes/macrophages (ED1; Serotec, Oxford, UK) or a biotinylated monoclonal antibody against the T-cell receptor (TCR-αβ; Serotec), detected by a FITCconjugated streptavidin complex. Cross-reactivity was avoided by blocking the sections with mouse serum prior to the application of the second primary antibody.
Results

Clinical course
Weight loss and first clinical signs of the disease were detected 3 days after the injection of encephalitogenic T cells. Clinical disease severity peaked at days 4 and 5 with an average score of 3.5. First signs of clinical improvement were seen at day 6 (Fig. 1A) . Control rats showed no signs of disease during the experiment.
Validity of competitive PCR
To validate the competitive PCR assay used in the present study we demonstrated that variations of sample cDNA or standard DNA resulted in strictly proportional shifts of the PCR product ratios of the respective DNAs. Plotting the ratio of sample cDNA to standard DNA PCR products against the standard dilution in a double-logarithmic scale we obtained curves with slopes close to 1. Changes in the amount of either sample cDNA or standard DNA resulted in a parallel shift of the curves, thus implying that the amplification is proportional within the given proportions of sample cDNA and standard DNA (data not shown) (Bourde et al., 1996) .
Expression of 92-kDa gelatinase Quantitation of mRNA
A constitutive low level expression of 92-kDa gelatinase mRNA was found in normal rats and those injected with ovalbumin specific T cells, and up to day 2 following injection of encephalitogenic T cells. Elevated levels were found at day 3, with peak levels showing a tenfold increase above normal at day 4, coincident with peak clinical severity. Thereafter, mRNA levels declined to normal by day 7 and remained constant throughout the recovery phase of the disease (Fig. 1B) .
Proteolytic activity
To demonstrate that increased expression of 92-kDa gelatinase mRNA is associated with increased enzymatic activity, zymography of spinal cord tissue taken from animals at different stages of the disease was performed. A pronounced increase of 92-kDa gelatinase activity was observed in animals with severe clinical disease compared with lower scored animals, in line with the data obtained by competitive PCR. Thus, higher expression of mRNA was accompanied by augmented gelatin digestion.
In contrast, the activity of the 72-kDa gelatinase, which is detected in the same experiment, appeared to be constitutively expressed throughout all time points, the size of the unstained bands remaining constant (Fig. 2) .
Immunohistochemistry
In control animals and animals with a clinical score of 0, no immunoreactivity for the 92-kDa gelatinase could be detected. In AT-EAE, positive signals could first be seen at day 3; they increased until day 4 and 5, and decreased at day 7 to disappear by day 11. At day 3, in animals with a clinical score of 2, immunoreactivity was primarily found along the meninges and around blood vessels. Some positive signals could also be seen in the white and grey matter. Immunoreactivity was localized to cells with round nuclei, probably mononuclear invading cells, but also in the extracellular space. At the peak of the disease, around days 4 and 5, more positive cells could be detected in the white and grey matter, with less immunoreactivity in the meninges. Moreover, strong reactivity was noticeably found along the vessels. The distribution pattern of immunoreactive cells closely paralleled the density of infiltrating mononuclear cells. By day 7, the cellular and extracellular signal intensity and the number of positive cells decreased, with only a few signals along the meninges left. By day 11, all immunoreactivity had disappeared (Fig. 3) . Throughout the entire course of the disease, no immunoreactive neurons were discernible. Control sections, after omission of the primary antibody, showed only background staining.
Immunofluorescence double labelling was performed in sections which revealed increased 92-kDa gelatinase immunoreactivity and it confirmed the distribution pattern of MMP-9 as described above. However, MMP-9 could not be co-localized with either ED1 ϩ monocytes/macrophages or TCRαβ ϩ T cells (not shown).
Other matrix metalloproteinases
To investigate whether other MMPs besides MMP-9 are regulated during the course of AT-EAE we studied the mRNA expression of matrilysin, collagenase-3, 72-kDa gelatinase, and stromelysin-1 and -3. The latter four MMPs were constitutively expressed at low levels, and did not exhibit any increase in mRNA levels during the clinical course of AT-EAE. Of these, the 72-kDa gelatinase was the most abundant, expressing slightly higher levels compared with rat collagenase, stromelysin-1 and -3. The mRNA expression pattern of the 72-kDa gelatinase underlines the constitutively low proteinase activity measured by gelatin zymography.
In contrast, matrilysin was found to be strongly upregulated (100-fold) with a peak of mRNA expression 4 days after injection of encephalitogenic T cells, returning to initial levels by day 7 and remaining constantly low throughout the recovery phase of the disease (Fig. 1C) .
Discussion
In the present study we investigated the expression of the 92-kDa gelatinase and other MMPs in the inflamed spinal cord of rats with EAE using a competitive PCR assay. As pointed out elsewhere (Bourde et al., 1996) , quantitative competitive PCR assays should follow certain theoretical requirements (Raemaykers, 1993) to be useful tools and produce meaningful results. By independent variation of standard and cDNA template concentrations and plotting the ratios of the respective PCR products in a double logarithmic manner, we obtained linear curves with slopes close to 1 and proportional parallel shifts of the curves, thus confirming the reliability of the semiquantitative competitive PCR assay used in the present study.
The time course of 92-kDa gelatinase expression in EAE, including mRNA expression, immunoreactive protein and enzyme activity, closely followed the time course of clinical Fig. 3 Immunohistochemistry for 92-kDa gelatinase in the spinal cord of Lewis rats. Animal at day 2 post-injection with a clinical score of 0 showing no immunoreactivity (A), whereas at day 3 (score 2-3), positive signals for MMP-9 can primarily be found along the meninges and around blood vessels (B). At the peak of clinical severity, day 4, immunoreactivity can be localized to infiltrating cells within the white and grey matter (C), to disappear by day 11 (D). Higher magnifications of a vessel from an animal at day 3 (E) and cellular infiltrates at day 4 (F) clearly link positive immunoreactivity to vessels (E) and to infiltrating mononuclear cells (F). Magnifications: A-D, ϫ200; E-F, ϫ600.
disease in the present study. Furthermore, the distribution pattern of positive immunoreactivity for MMP-9 with early localization to the meninges, perivascular spaces and white matter tracts, and later the central grey matter of the spinal cord, was coincident with the topographical distribution of inflammatory infiltrates in EAE (Lassmann et al., 1991) . However, while some positive staining could be associated with round cellular nuclei, suggestive of infiltrating mononuclear cells, we failed to co-localize immunoreactivity for the 92-kDa gelatinase with T-cell or macrophage antigens. In addition, typical perineuronal microglial cellular profiles, presumed astrocytes and neurons themselves were unstained at all time points studied. These findings suggest a predominantly extracellular localization of enzyme secreted from an as yet unknown cellular source. However, the close association of immunoreactivity with mononuclear cellular infiltrates points to infiltrating macrophages and T cells, the prime effector cells in EAE (Huitinga et al., 1990; Raine, 1991) , being the predominant producers of MMP-9. This assumption is consistent with previous investigations where macrophages in multiple sclerosis plaques (Cuzner et al., 1996) , neutrophils (Nielsen et al., 1996) , monocytes (Welgus et al., 1990) and T cells (Leppert et al., 1995) were found to secrete 92-kDa gelatinase. In contrast, microglial cells were previously noted to express MMP-9 in multiple sclerosis lesions, and motor neurons in the spinal cord were described as a potential source of MMP-9 production in amylotrophic lateral sclerosis (Lim et al., 1996) . It is unclear, at present, whether technical issues, species differences or differential regulatory events during diverse biological situations account for these discrepancies. Nevertheless, we could detect proteolytic activity of the 92-kDa gelatinase in our encephalitogenic T-cell line after stimulation with interleukin-2 by zymography (data not shown), pointing to this cell population as potential producers of this MMP. However, further studies are needed to elucidate the exact cellular sources of MMPs in the pathogenesis of neuroinflammatory diseases.
The time course and cellular distribution of MMP-9 in EAE, as described in the present study, suggests biological effects in early and central stages of the disease process that are associated with inflammatory infiltration. As shown by previous in vitro studies, T-cell migration can be mediated by gelatinases (Leppert et al., 1995) , and in vivo gelatinase injection into the brain resulted in disruption of the BBB (Rosenberg et al., 1994) . The predominant localization of MMP-9 around blood vessels in the present study suggests that MMP-9 might be physiologically involved in the disruption of vascular basement membranes (Gijbels et al., 1993) and the BBB, paving the way for infiltrating haematogenous cells. Since migration of autoreactive T cells from blood to the CNS is considered of paramount importance in the genesis of autoimmune inflammatory demyelination, such an action of MMPs would imply that they have a strategic role in this process (Hartung, 1995) . Another potential target for MMP-9 action in the pathogenesis of neuroinflammatory disorders is the myelin sheath. As shown previously, MMP-9 and other MMPs are known to degrade MBP in vitro (Proost et al., 1993; Chandler et al., 1995) and they could therefore contribute to demyelination. However, since MBP is located at the cytoplasmic face of the myelin membrane, there is little chance that this would represent a primary mechanism of demyelination. Furthermore, little or no demyelination is seen in the Lewis rat AT-EAE model, and these animals recover spontaneously and completely without residual deficits (Wekerle et al., 1994) . Finally, MMP-9 may be involved in the regulation of other bioactive proteins including cytokines (Opdenakker and van Damme, 1994; Hartung et al., 1992; Ries and Petrides, 1995) . Thus, release of the myelinotoxic and phlogogenic cytokine TNF-α appears to be dependent on an MMP-like mechanism of action (Gearing et al., 1994; Mohler et al., 1994) , indicating an even more complex involvement of MMPs in neuroinflammation. However, the recently described TNF-α converting enzyme (TACE) has been shown to be a disintegrin metalloproteinase with notable sequence identity to the adamalysin family of metalloproteinases, implying TACE to be more likely a novel metalloproteinase, distinct from the hitherto known 'classical' MMPs (Black et al., 1997; Moss et al., 1997) . Further studies are needed to elucidate the contributory effects of known MMPs to the release of surface cytokines and receptors, which markedly impact on the orchestration of immunoinflammatory responses.
Recently, Cuzner et al. (1996) described the expression of MMP-9 in post-mortem multiple sclerosis lesions and related it to the degree of inflammation. It is obvious that such a study can provide a focused view at only one time point in the disease process of which the precise pathobiological history cannot be ascertained. Hence, it is impossible to define the exact relation to the stage of the ongoing disease. By contrast, in the present study we have investigated the temporospatial expression pattern of MMP-9 during the entire development of acute inflammation in the CNS, providing a better insight into the relationships between acute inflammation, severity of the ongoing disease and MMP expression in neuroinflammatory disorders such as multiple sclerosis.
To investigate whether other MMPs besides MMP-9 might also be regulated in experimental neuroinflammation, mRNA expression patterns of five other metalloproteinase were studied. Whereas matrilysin mRNA was clearly upregulated, with peak levels showing a 100-fold increase above the initial expression at maximum disease activity, the 72-kDa gelatinase, thought to be primarily involved in BBB disruption (Rosenberg et al., 1992) , was not modulated in the present study. Similarly, mRNAs for collagenase-3 and stromelysin-1 and -3 were found to be constitutively expressed at low levels but not regulated. Thus, MMPs in the brain, though all present at low levels even in normal tissue, do not respond to inflammatory stimuli in an all-or-none fashion; rather, they are differentially regulated (Kohn et al., 1994) during AT-EAE. What the role of selectively upregulated matrilysin might be in inflammation is poorly understood. A strong catalytic activity against a variety of extracellular matrix substrates such as proteoglycans, elastin, laminin and fibronectin has been described (Murphy et al., 1994) , and a potential role in monocyte extravasation and macrophage migration through interstitial tissue spaces was proposed (Busiek et al., 1995) . Increased levels of specific mRNA during EAE may suggest a potential involvement of matrilysin in such events.
The results of our present study are in accord with a recent report on MMP expression and its regulation by a hydroxamate-based inhibitor in actively induced EAE, where levels of MMP-9 and MMP-7 mRNA were found to be increased by 5-and 500-fold, respectively (Clements et al., 1997) . In contrast to the present findings, matrilysin mRNA levels remained increased during the recovery phase of actively induced EAE, a discrepancy which may be attributed to the difference in the animal models used.
This collective experimental evidence points to MMPs as potential targets for an effective treatment of multiple sclerosis eiher alone or in concert with other selective therapies. MMP inhibitors have, indeed, been shown to efficiently ameliorate EAE (Gijbels et al., 1994; Hewson et al., 1995) and to reduce BBB breakdown, inflammatory cell recruitment, and myelin damage significantly (Matyszak and Perry, 1996) . Moreover, in vitro studies suggest an inhibitory effect of gelatinase secretion as a potential therapeutic mechanism of IFN-β-1b (Leppert et al., 1996) . Further knowledge of specific temporospatial expression patterns of selected MMPs might help to design inhibitors that could be administered at critical points in the evolution of immune mediated damage to the CNS. It is hoped that such compounds may enlarge our therapeutic armamentarium for neuroinflammatory diseases.
